Interleukin on track to commercialize periodontal disease test
from Boston Business Journal
It was a close call for Interleukin Genetics Inc., but the company said it is on track. The Waltham, Mass., diagnostics company received word that its University of Michigan study has been accepted for publication with just a week to go. The study, which showed the value of PST — a genetic test that measures the risk of developing periodontal disease — was the last piece the company needed to be able to move forward. The study showed the test guided better prevention of dental disease and more efficient health delivery.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063